Stock Financial Ratios, Dividends, Split History

FINL / Finish Line, Inc. (THE) financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price13.51
Volume5,145,900.00
Market Cap ($M)546.16
Enterprise Value ($M)452.78
Book Value ($M)450.99
Book Value / Share11.13
Price / Book1.21
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 40,516,631
Common Stock Shares Outstanding 40,370,000
Weighted Average Number Of Diluted Shares Outstanding 40,339
Weighted Average Number Diluted Shares Outstanding Adjustment 58
Weighted Average Number Of Shares Outstanding Basic 40,281
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.03
Return on Assets (ROA)0.02
Return on Equity (ROE)0.03
Balance Sheet (mrq) ($M)
Assets675.03
Liabilities224.04
Quick Ratio0.82
Current Ratio2.71
Income Statement (mra) ($M)
Sales Revenue Net1,838,956,000.00
Disposal Group Including Discontinued Operation Revenue0.00
Operating Income8.92
Net Income14.41
Earnings Per Share Basic0.35
Earnings Per Share Diluted0.35
Cash Flow Statement (mra) ($M)
Cash From Operations77.74
Cash from Investing-51.96
Cash from Financing-51.96
Identifiers and Descriptors
CUSIP317923100
Central Index Key (CIK)886137
Related CUSIPS
317923950 031792310 317923900
Industry Groups
SIC 5661 - Shoe Stores

Split History

Stock splits are used by Finish Line, Inc. (THE) to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
FINL: The Finish Line Analysis and Research Report

2018-02-22 - Asif

The Company is a premium retailer of athletic shoes, apparel, and accessories for men, women, and kids, throughout the United States, Guam, and Puerto Rico, through multiple operating segments. Headquartered in Indianapolis, Finish Line runs approximately 950 branded locations in U.S. malls and shops inside Macy’s department stores. Finish Line employs more than 14,000 associates who connect customers to sneaker culture through style and sport Brick and mortar comparable sales are the change in net sales year over year for the reporting periods presented from Finish Line stores open longer than one year, beginning in the thirteenth month of a store’s operation. Expanded stores are excluded from the brick and mortar comparable sales calculation until the thirteenth month following the re-opening of the store and temporarily closed stores are excluded during the months that the store is closed. Brick and mortar comparable sales do not include sales from shops within department stores....

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Related News Stories

Stocks To Watch: Don't Sleep On Vienna

2018-06-16 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (526-2)

Flop, Platoon or Finish Line? The 3 kinds of soccer dive, according to a UVic prof

2018-06-13 cbc.ca
The 2018 FIFA Men's World Cup begins in Russia on Thursday and soccer fans are bracing themselves for the notorious tradition of diving: the way players often fall over, writhe and scream in fake pain to score an advantage. (5-0)

No Assault Riffles, No Problem At Dick's Sporting Goods

2018-06-05 seekingalpha
Dick's shrugged of fears of boycotts and no longer selling assault riffles to post sold top-line growth numbers. (23-0)

Lululemon: Beautiful Rebound Story Running Its Course

2018-06-04 seekingalpha
Lululemon's recent earnings announcement reinforced the idea that the company has returned to the very top in sportswear retailing. (10-0)

Hibbett Is Hanging On

2018-06-04 seekingalpha
Hibbett has done a very nice job of quickly patching the holes on what looked like an eroding business model. (19-0)

CUSIP: 317923100